Background: The prostate is the site of problems that have great clinical relevance. Beside this, the alterations in their volume can be divided into benign or malignant pathologies, but of multifactorial cause and there is no examination that alone is reliable for the diagnosis. Despite the evolution of the various methods of diagnostic imaging in the evaluation of pelvic diseases, the diagnosis of prostate cancer still requires histological confirmation obtained by transrectal ultrasound guided biopsy, a procedure that is generally safe and well tolerated by the patients. The most common histological type found in prostate biopsies is adenocarcinoma. Methodology: The objective of this study was to study the values of density of the prostate-specific antigen (DPSA) compared to histopathological results of prostate biopsy, patients attended at the Urology Outpatient Clinic of the Luiz Gioseffi Jannuzzi School Hospital from 1999 to 2007, using Exploratory, retrospective and documentary descriptive study. The sample was divided into groups of patients with adenocarcinoma and patients without adenocarcinoma, who presented only benign prostatic hyperplasia. Results: Of the 251 patients undergoing prostate biopsy, 124 were diagnosed with adenocarcinoma and 127 without adenocarcinoma.
It was observed in this study that the DPSA was higher in adenocarcinoma than in the cases of patients with prostatic hyperplasia alone, and could therefore be used as an auxiliary tool in both diagnosis and follow-up of patients with adenocarcinoma. Conclusion: In this study, it can be observed that DPSA was higher in patients presenting with adenocarcinoma than in patients presenting only Benign Prostatic Hyperplasia (BPH), reinforcing its promising role to assist in the diagnosis and follow-up of patients with adenocarcinoma.
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Introduction
The prostate is a small organ about 3 cm long that is located in the pelvis and weighs about 20 g in the healthy adult. Its constitution corresponds to 2/3 glandular and 1/3 fibromuscular, also having a dense fibrous capsule, surrounded by a continuous prostatic sheath with puboprostatic ligaments. Among the pathologies that afflict it, cancer, benign hyperplasia and prostatites are noteworthy [1] .
In Brazil, the increase in life expectancy, the improvement and evolution of the diagnostic methods and the quality of the country's information systems achieved in recent years are related to the dissemination of prostate cancer screening with rectal examination, dosage of the specific prostatic antigen (PSA) and transrectal ultrasonography (USG-TR) to assist the best biopsy area, which explains the increase in incidence rates over the years [4] .
PSA is the most important marker for the diagnosis and initial follow-up of prostate cancer, despite the difficulties to distinguish between cases of benign prostatic hyperplasia (BPH) and a considerable number of false positives and unnecessary biopsies [5] . In contrast, more tools were introduced to aid in screening and decrease the number of unnecessary biopsies such as dosage and calculation of the PSA Free/PSA Total Ratio, PSA Velocity (VPSA) and PSA Density (DPSA) [7] .
VPSA is defined as a change in serum PSA values over a period of time and is generally less than 0.10 ng/mL. However, BPH interferes with the speed of PSA due to rapid growth velocity, leading to increased PSA due to enlargement of the gland and not due to tumor enlargement [8] .
DPSA was introduced to increase the sensitivity and specificity of PSA and is expressed by the ratio of prostate volume to serum PSA value assessed by USG-TR, reflecting activity in the prostate transition zone. Its limitations are the failure to accurately determine the prostate volume by USG-TR and the variability of glandular content versus stroma that varies from gland to gland. In the calculation of DPSA, serum PSA (ng/mL) is divided by the prostate volume (cm 3   ) evaluated by USG-TR ultrasound with cut-off point has been 0.15 ng/mL [9] [10].
The objective of this study was to study the DPSA values comparing to histopathological results of prostate biopsy of patients followed at the Urology Outpatient Clinic of the Luiz Gioseffi Jannuzzi School Hospital (HELGJ) from 1999 to 2007.
Methodology
This study was initially carried out a literary review on the subject in books and articles published in periodicals indexed to PubMed and Scielo. After that, a descriptive exploratory and retrospective documentary study was carried out.
Data were collected from patients seen at the Outpatient Clinic at HELGJ and with examinations performed during between 1999 and 2007 due to the greater number of information available in the medical records of this period. As selection criteria for inclusion in the study were those who used PSA dosage, DPSA and prostate biopsy, and those patient records that did not contain any of these criteria were excluded from the study.
In order to collect data, the following variables were evaluated: laboratory values of PSA (ng/mL), of DPSA (ng/mL)-which correspond to the division between total PSA and prostate volume (cm 
Results
A total of 328 medical records were analyzed, of which 77 were excluded because they did not contain data that contributed to the study. The mean age of the pa- We also tested the variability of the groups through ANOVA. The critical F > F value means that there is a significant relationship between the DPSA value (Table 2 and Table 3 ).
In the drawing of the graph, isolated values were extracted in the two samples, as they generated discrepancy. There was an increase in DPSA values proportional to the increasing number of patients with adenocarcinoma and BPH, respectively, but this increase was much more pronounced in patients in the adenocarcinoma group (Figure 1 ).
Discussion
Due to the considerable prevalence of the histological type, this study will treat from here prostate cancer as adenocarcinoma, where the levels of PSA in the blood plasma are larger and there is correlation with the prostate volume [11] .
According to Rhoden and Averbeck (2010), the mean age at which prostate cancer that may be mentioned include inadequate feeding, smoking, alcoholic beverage intake, and average time spent on care for more than 30 days. Caucasian, low schooling, retirement and family cohabitation were predominant characteristics in their patients [13] .
On the other hand, in relation to the value of PSA, NettoJr and Wroclawski (2010) and Nassif (2009) admit that normal is up to 4 ng/ml (11) (14), much lower than that found in our study.
We did not find in the present sample cases of hyperplasia with DPSA > 4.33, which was found in only one patient in the present case, considered, therefore, outside the standard curve.
In the patients diagnosed with adenocarcinoma, 23 had DPSA < 0.18, corresponding to 18% of the series, which demonstrates an intimate relationship between the elevation of DPSA and prostate cancer, corroborating with studies by Nassif et al. (2013) and Moreira (2015) [5] [10] .
It was also evidencing higher prostate volume in patients with benign tumors, which may be related to the higher prevalence of BPH. In this study, it can be observed that DPSA was higher in patients presenting with adenocarcinoma than in patients presenting only BPH, reinforcing its promising role to assist in the diagnosis and follow-up of patients with adenocarcinoma.
Final Considerations
However, among the many uncertainties that are encountered when dealing with patients known to be carriers of prostate cancer, are the parameters to be used in their therapeutic conduction. There are no known tests that are highly reliable in isolation.
A fact to be taken into account is that the USG-TR biopsy examination is subject to method failures and has not been evaluated for hormone suppression therapy, which would directly influence the results.
